Hearing assesment in children after intrauterine exposure to platinum-based treatment of pregnant cancer patients: A study from the International Network on Cancer, Infertility and Pregnancy
Identifikátory výsledku
Kód výsledku v IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064173%3A_____%2F25%3A43928937" target="_blank" >RIV/00064173:_____/25:43928937 - isvavai.cz</a>
Nalezeny alternativní kódy
RIV/00216208:11120/25:43928937
Výsledek na webu
<a href="https://doi.org/10.1186/s12887-025-05992-z" target="_blank" >https://doi.org/10.1186/s12887-025-05992-z</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1186/s12887-025-05992-z" target="_blank" >10.1186/s12887-025-05992-z</a>
Alternativní jazyky
Jazyk výsledku
angličtina
Název v původním jazyce
Hearing assesment in children after intrauterine exposure to platinum-based treatment of pregnant cancer patients: A study from the International Network on Cancer, Infertility and Pregnancy
Popis výsledku v původním jazyce
BACKGROUND: Literature on the effects of prenatal exposure to platinum-based chemotherapy on the auditory capacity of the offspring is scarce. The current study aims to describe the occurrence of hearing impairment in a well-documented series of children who underwent audiological testing. METHODS: An international, descriptive multicentre study using oncological, obstetrical, and neonatal data registered by the International Network of Cancer Infertility and Pregnancy database, was performed. The offspring (aged >= 4 years) underwent pure tone audiometry. Audiological outcomes were registered after expert review, using international standardized audiological grading as developed for platinum exposed childhood cancer patients: the Muenster criteria and the International Society for Paediatric Oncology classification. Platinum-induced hearing loss was defined as bilateral hearing loss, starting at 8 kHz and without middle ear problems confirmed by tympanometry or otoscopy. FINDINGS: Twenty-five children were included of which 17 children (68%) had been exposed to cisplatin and 8 (32%) to carboplatin, none to both. Median gestational age at start maternal treatment was 22 weeks (range, 14-31). Median gestational age at delivery was 35 weeks (range, 31-39), and median birth weight was 2345 g (range, 1526-3360). Neonatal hearing screening, performed in 10 children (40%), showed no hearing loss. At a median age of 6.0 years (range, 4.0-28(.)0), 6 children (24%) revealed bilateral hearing loss, using cut-off values of Muenster grade >= 2b and SIOP grade >= 2. INTERPRETATION: Antenatal exposure to platinum-based chemotherapy is associated with hearing loss in a subset of the offspring. Prospective longitudinal standardized surveillance of auditory function is advised, starting after birth. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12887-025-05992-z.
Název v anglickém jazyce
Hearing assesment in children after intrauterine exposure to platinum-based treatment of pregnant cancer patients: A study from the International Network on Cancer, Infertility and Pregnancy
Popis výsledku anglicky
BACKGROUND: Literature on the effects of prenatal exposure to platinum-based chemotherapy on the auditory capacity of the offspring is scarce. The current study aims to describe the occurrence of hearing impairment in a well-documented series of children who underwent audiological testing. METHODS: An international, descriptive multicentre study using oncological, obstetrical, and neonatal data registered by the International Network of Cancer Infertility and Pregnancy database, was performed. The offspring (aged >= 4 years) underwent pure tone audiometry. Audiological outcomes were registered after expert review, using international standardized audiological grading as developed for platinum exposed childhood cancer patients: the Muenster criteria and the International Society for Paediatric Oncology classification. Platinum-induced hearing loss was defined as bilateral hearing loss, starting at 8 kHz and without middle ear problems confirmed by tympanometry or otoscopy. FINDINGS: Twenty-five children were included of which 17 children (68%) had been exposed to cisplatin and 8 (32%) to carboplatin, none to both. Median gestational age at start maternal treatment was 22 weeks (range, 14-31). Median gestational age at delivery was 35 weeks (range, 31-39), and median birth weight was 2345 g (range, 1526-3360). Neonatal hearing screening, performed in 10 children (40%), showed no hearing loss. At a median age of 6.0 years (range, 4.0-28(.)0), 6 children (24%) revealed bilateral hearing loss, using cut-off values of Muenster grade >= 2b and SIOP grade >= 2. INTERPRETATION: Antenatal exposure to platinum-based chemotherapy is associated with hearing loss in a subset of the offspring. Prospective longitudinal standardized surveillance of auditory function is advised, starting after birth. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12887-025-05992-z.
Klasifikace
Druh
J<sub>imp</sub> - Článek v periodiku v databázi Web of Science
CEP obor
—
OECD FORD obor
30214 - Obstetrics and gynaecology
Návaznosti výsledku
Projekt
—
Návaznosti
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Ostatní
Rok uplatnění
2025
Kód důvěrnosti údajů
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Údaje specifické pro druh výsledku
Název periodika
BMC Pediatrics
ISSN
1471-2431
e-ISSN
1471-2431
Svazek periodika
25
Číslo periodika v rámci svazku
October
Stát vydavatele periodika
GB - Spojené království Velké Británie a Severního Irska
Počet stran výsledku
11
Strana od-do
703
Kód UT WoS článku
001586849300049
EID výsledku v databázi Scopus
2-s2.0-105017817780